In these cancers the overexpression of c‐Met is well documented, for example, 35%–72% for lung adenocarcinoma, 38% for lung squamous cell carcinoma, 23% for hormone‐refractory prostate cancer, 72% for prostate cancer bone metastases, up to 80% for breast cancer, and 10%–75% for colon/rectum cancer,9, 10, 11, 12 resulting in a very large target clinical population per year of millions of potential patients worldwide that could benefit from novel c‐Met imaging agents. Here, MET is linked to prostate carcinoma.